ClearPoint Neuro announces publication on Prism Neuro Laser Therapy System

ClearPoint Neuro announced that preclinical results of an in vivo validation study have been published in the Journal of Neurosurgery. These data demonstrate that the ClearPoint Prism Neuro Laser Therapy System provides accurate, near real-time temperature of the brain tissue with a mean absolute error of less than1 degrees C. Additionally, the morphology of the lesion, as visualized by Thermoguide MR-thermometry software, correlated well with histopathology. The research was conducted by the Company and its Swedish partner, Clinical Laserthermia Systems AB, with Dr. John Rolston leading the study as Principal Investigator. The aim of the study was to evaluate the safety, accuracy, and efficacy of the Prism System. This was achieved by 1) demonstrating a predicted safety margin via survival histology; 2) determining the Thermal Damage Thresholds that best predict irreversible tissue damage based on said histology; and 3) evaluating the accuracy of temperature prediction compared to actual temperature changes in vivo. The Prism System features the only non-cooled neurosurgical laser applicators on the market. ClearPoint’s next-generation laser applicator technology eliminates the need for external cooling, simplifying setup, reducing power and ablation time, lessening imaging artifact, and enabling more efficient workflows. Currently, Prism is in limited market release at select academic medical centers across the United States.